Efficacy and Safety of Hydroxychloroquine for the Treatment of COVID-19: An empirical study
DOI:
https://doi.org/10.56294/hl2025626Keywords:
COVID-19, Hydroxychloroquine, chloroquine, Efficacy and Safety, lung computed tomography (CT)Abstract
The new coronavirus disease epidemic of 2019 (COVID-19) has spread worldwide. A quick solution to meet the urgent demand for effective treatment may be drug repurposing. To treat COVID-19, evaluated the clinical effectiveness of hydroxychloroquine and chloroquine. The individuals that received a modest COVID-19 score were randomized to obtain the control therapy or hydroxychloroquine 800 milligrams once daily on Day 7 and 250 milligrams for nine days, except the evaluated the clinical effectiveness of hydrochloride and chlorin equine. Compared to the control group (CtrlGrp) (Group 3), adverse reactions were observed more frequently in those taking chloroquine (Group 1) and hydroxychloroquine (Group 2). The time to clinical recovery (TTCR) was shortened in the Group 1 relation to the CtrlGrp. In the Group 2, there was a tendency toward lower TTCR. Chloroquine and Group 2 reached viral RNA negative substantially faster than the CtrlGrp. The typical instances to become RNA negative in the groups treated with chloroquine, hydroxychloroquine, and controls comprised two days, two weeks, and seven days, correspondingly. Both the length of hospitalization and the results of the lung computed tomography (CT) indicated improvements in the hydroxychloroquine and chloroquine pharmacologic categories. This research provides evidence that hydrochlorothiazide may be used to treat mild COVID-19, and it complements more excellent investigations.
References
1. Risch HA. Hydroxychloroquine in Early Treatment of High Risk COVID-19 Outpatients: Efficacy and Safety Evidence. Sixth version. Available online: https://earlycovidcare. org/wp-content/uploads/2021/09/Evidence-Brief-Risch-v6. pdf (accessed on 6 May 2022). 2021 Jun 17.
2. Sogut O, Can MM, Guven R, Kaplan O, Ergenc H, Umit TB, Demir O, Kaya M, Akdemir T, Cakmak S. Safety and efficacy of hydroxychloroquine in 152 outpatients with confirmed COVID-19: a pilot observational study. The American journal of emergency medicine. 2021 Feb 1;40:41-6. https://doi.org/10.1016/j.ajem.2020.12.014
3. Esper RB, da Silva RS, Oikawa FT, Castro MM, Razuk-Filho A, Batista PB, Lotze S, da Rocha CN, de Sá Cunha Filho R, de Oliveira S, Ribeiro PL. Empirical treatment with hydroxychloroquine and azithromycin for suspected cases of COVID-19 followed-up by telemedicine. Prevent Senior Institute SP, Brazil, ed. São Paulo. 2020 Jul 28;25.
4. Kim MS, An MH, Kim WJ, Hwang TH. Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis. PLoS medicine. 2020 Dec 30;17(12):e1003501. https://doi.org/10.1371/journal.pmed.1003501
5. Sultana J, Cutroneo PM, Crisafulli S, Puglisi G, Caramori G, Trifirò G. Azithromycin in COVID-19 patients: pharmacological mechanism, clinical evidence and prescribing guidelines. Drug safety. 2020 Aug;43:691-8. https://doi.org/10.1007/s40264-020-00976-7
6. Di Stefano L, Ogburn EL, Ram M, Scharfstein DO, Li T, Khanal P, Baksh SN, McBee N, Gruber J, Gildea MR, Clark MR. Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysis. PLoS One. 2022 Sep 29;17(9):e0273526. https://doi.org/10.1371/journal.pone.0273526
7. Abd-Elsalam S, Esmail ES, Khalaf M, Abdo EF, Medhat MA, Abd El Ghafar MS, Ahmed OA, Soliman S, Serangawy GN, Alboraie M. Hydroxychloroquine in the treatment of COVID-19: a multicenter randomized controlled study. The American journal of tropical medicine and hygiene. 2020 Aug 14;103(4):1635. https://doi.org/10.4269/ajtmh.20-0873
8. Das RR, Jaiswal N, Dev N, Jaiswal N, Naik SS, Sankar J. Efficacy and safety of anti-malarial drugs (chloroquine and hydroxy-chloroquine) in treatment of COVID-19 infection: a systematic review and meta-analysis. Frontiers in medicine. 2020 Jul 29;7:482. https://doi.org/10.3389/fmed.2020.00482
9. Chen L, Zhang ZY, Fu JG, Feng ZP, Zhang SZ, Han QY, Zhang XB, Xiao X, Chen HM, Liu LL, Chen XL. Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study. Medrxiv. 2020 Jun 22:2020-06. https://doi.org/10.1101/2020.06.19.20136093
10. Hernandez AV, Roman YM, Pasupuleti V, Barboza JJ, White CM. Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review. Annals of internal medicine. 2020 Aug 18;173(4):287-96. https://doi.org/10.7326/M20-2496
11. Alexander PE, Debono VB, Mammen MJ, Iorio A, Aryal K, Deng D, Brocard E, Alhazzani W. COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. Journal of clinical epidemiology. 2020 Jul 1;123:120-6. https://doi.org/10.1016/j.jclinepi.2020.04.016
12. Thémans P, Belkhir L, Dauby N, Yombi JC, De Greef J, Delongie KA, Vandeputte M, Nasreddine R, Wittebole X, Wuillaume F, Lescrainier C. Population pharmacokinetics of hydroxychloroquine in COVID-19 patients: implications for dose optimization. European journal of drug metabolism and pharmacokinetics. 2020 Dec;45:703-13. https://doi.org/10.1007/s13318-020-00648-y
13. Sri IG, Marzuki JE, Angelia F, Siane A, Sary LD, Yohanes L, Widyastuti R, Nova R, Simorangkir DS, Safitri Y, Aliska G. Antiviral treatment of COVID-19: a clinical pharmacology narrative review. Medical journal of Indonesia. 2020 Jul 18;29(3):332-45. https://doi.org/10.13181/mji.rev.204652
14. Derwand R, Scholz M, Zelenko V. COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study. International journal of antimicrobial agents. 2020 Dec 1;56(6):106214. https://doi.org/10.1016/j.ijantimicag.2020.106214
15. Rughiniş C, Dima L, Vasile S. Hydroxychloroquine and COVID-19: lack of efficacy and the social construction of plausibility. American journal of therapeutics. 2020 Nov 1;27(6):e573-83. https://doi.org/10.1097/MJT.0000000000001294
16. Shamshirian A, Hessami A, Heydari K, Alizadeh-Navaei R, Ebrahimzadeh MA, Yip GW, Ghasemian R, Behnamfar M, Baradaran H, Aboufazeli E, Jafarpour H. Hydroxychloroquine versus COVID-19: a periodic systematic review and meta-analysis. MedRxiv. 2020 Apr 20:2020-04. https://doi.org/10.1101/2020.04.14.20065276
17. Luo E, Zhang D, Luo H, Liu B, Zhao K, Zhao Y, Bian Y, Wang Y. Treatment efficacy analysis of traditional Chinese medicine for novel coronavirus pneumonia (COVID-19): an empirical study from Wuhan, Hubei Province, China. Chinese medicine. 2020 Dec;15:1-3. https://doi.org/10.1186/s13020-020-00317-x
18. Wadaa-Allah A, Emhamed MS, Sadeq MA, Ben Hadj Dahman N, Ullah I, Farrag NS, Negida A. Efficacy of the current investigational drugs for the treatment of COVID-19: a scoping review. Annals of medicine. 2021 Jan 1;53(1):318-34. https://doi.org/10.1080/07853890.2021.1875500
19. Martínez-Sánchez N, De la Calle Fernández-Miranda M, Bartha JL. Safety profile of treatments administered in COVID 19 infection in pregnant women. Clínica e Investigación en Ginecología y Obstetricia. 2021 Jul 1;48(3):100663. https://doi.org/10.1016/j.gine.2021.01.004
20. Yen CY, Lee PH, Yen JC, Chen CC, Hu HY, Tseng PC. Current screening practice in patients under long-term hydroxychloroquine medication in Taiwan: A nationwide population-based cohort study. Medicine. 2019 Apr 1;98(14):e15122. https://doi.org/10.1097/MD.0000000000015122
21. Kuipers MT, van Zwieten R, Heijmans J, Rutten CE, de Heer K, Kater AP, Nur E. Glucose‐6‐phosphate dehydrogenase deficiency‐associated hemolysis and methemoglobinemia in a COVID‐19 patient treated with chloroquine. American journal of hematology. 2020 Jun 18;95(8):E194. https://doi.org/10.1002/ajh.25862
22. Maroušek J, Kolář L, Strunecký O, Kopecký M, Bartoš P, Maroušková A, Cudlínová E, Konvalina P, Šoch M, Moudrý Jr J, Vaníčková R. Modified biochars present an economic challenge to phosphate management in wastewater treatment plants. Journal of Cleaner Production. 2020 Nov 1;272:123015. https://doi.org/10.1016/j.jclepro.2020.123015
23. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical infectious diseases. 2020 Jul 28;71(15):732-9. https://doi.org/10.1093/cid/ciaa237
24. Al-Horani RA, Kar S, Aliter KF. Potential anti-COVID-19 therapeutics that block the early stage of the viral life cycle: structures, mechanisms, and clinical trials. International Journal of Molecular Sciences. 2020 Jul 23;21(15):5224. https://doi.org/10.3390/ijms21155224.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Vivek Saraswat, Pradeepta Sekhar Patro , Sourav Rampal , Madireddy Sirisha , Mukesh Sharma , Monika (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
